The imaging technique at the heart of the study is ¹⁸F-fluorodeoxyglucose PET/CT, a hybrid technology that pairs the functional sensitivity of positron emission tomography with the anatomical detail of computed tomography. Fluorine-18 labelled fluorodeoxyglucose is a radioactive glucose analogue that cells import through the same transporters they use for ordinary sugar. Because most cancer cells run their metabolism on glycolysis even when oxygen is plentiful, the Warburg effect, malignant tissue accumulates the tracer far more avidly than surrounding healthy structures. A detector ring records the decay of the fluorine-18 isotope, and the resulting signal is converted into standardised uptake values, or SUVs, which quantify how intensely a given lesion traps glucose relative to the injected dose and body mass. The maximum standardised uptake value, SUVmax, captures the single hottest pixel within a lesion and has long served as a convenient, if imperfect, proxy for metabolic aggressiveness.

The Zhejiang team, led by Yunqi Zhu and corresponding author Xinhui Su, assembled thirty treatment-naïve patients with histologically confirmed testicular germ cell tumours who had undergone ¹⁸F-FDG PET/CT before any antitumour therapy. Twelve carried a diagnosis of seminoma and eighteen had non-seminomatous germ cell tumours, a group that encompasses embryonal carcinoma, yolk sac tumour, choriocarcinoma and other histologies, often in mixtures. Because the patients had not yet received chemotherapy, surgery or radiotherapy, the scans offered an unfiltered view of each tumour’s native metabolism, free from the confounding effects of treatment-induced inflammation or necrosis that plague post-therapy imaging.

The headline result is hard to overstate. Non-seminomatous tumours showed a median primary-tumour SUVmax of 16.66, compared with just 8.41 for seminomas, a difference that reached statistical significance at P equals 0.007. When the researchers looked instead at the hottest lesion anywhere in each patient, the gap widened further: 21.91 versus 8.41, with P below 0.001. In other words, the non-seminomatous tumours were burning through glucose at roughly twice the rate of their seminoma counterparts, a metabolic distinction that mirrors the known biological gulf between these entities. Non-seminomatous germ cell tumours tend to be more proliferative, more genetically chaotic and more prone to early haematogenous spread, and the PET data appear to capture that ferocity in a single number.

Disease extent itself was also strikingly different between the groups. Distant metastatic disease, classified as M1 under the American Joint Committee on Cancer staging system, was present in 55.6 percent of the non-seminomatous patients but only 8.3 percent of those with seminoma. This imbalance matters for interpretation, because a patient-level measurement such as the highest-lesion SUVmax can be inflated simply by the presence of a metabolically hot metastasis rather than by any intrinsic property of the primary tumour. The investigators were alert to this pitfall and designed their analyses accordingly, performing receiver operating characteristic analysis to compare diagnostic performance, restricting analyses to patients without distant metastases, and building exploratory multivariable models to adjust for tumour size and metastatic status.

Those sensitivity analyses proved revealing. When the analysis was confined to patients with M0 disease, meaning no distant metastases, the primary-tumour SUVmax remained significantly higher in non-seminomatous tumours, at 16.96 versus 8.00 with P equal to 0.001. However, the apparent advantage of the patient-level highest-lesion SUVmax over the primary-tumour measurement shrank dramatically: the difference in area under the receiver operating characteristic curve fell from 0.148 in the full cohort to just 0.023 in the metastasis-free subgroup. This tells an important story about what each metric actually measures. The highest-lesion SUVmax looked like a superb discriminator across all comers, achieving an apparent area under the curve of 0.944, but part of that performance was borrowed from the fact that metastatic spread is itself more common in non-seminomatous disease. The primary-tumour measurement, by contrast, appears to reflect genuine histology-linked biology.

The exploratory log-linear model drove the point home. After adjusting for primary-tumour size and M status, non-seminomatous tumours retained a higher primary-tumour SUVmax, with an adjusted geometric mean ratio of 1.67 relative to seminoma and a 95 percent confidence interval of 1.07 to 2.60, yielding P equal to 0.024. A geometric mean ratio of 1.67 implies that, on average, the non-seminomatous primary tumours took up roughly two-thirds more glucose than seminomas of comparable size and stage. For a single-centre study of thirty patients, this is an encouraging signal, though the authors are careful to label the modelling as exploratory and to emphasise that validation in larger independent cohorts is essential before any clinical application.

The study also placed PET-derived parameters alongside the traditional serum tumour markers that clinicians already use. Among individual biomarkers, the patient-level highest-lesion SUVmax showed the highest apparent discrimination with an area under the curve of 0.944, followed by alpha-fetoprotein at 0.910 and primary-tumour SUVmax at 0.796. Alpha-fetoprotein is a well-established hallmark of non-seminomatous histology, since seminomas do not produce it, so its strong showing is unsurprising. What is intriguing is that a purely metabolic imaging metric could rival a specific biochemical marker, suggesting that glucose avidity and embryonal differentiation are intertwined at a fundamental level. The researchers also computed a panel of volumetric parameters, including metabolic tumour volume, total lesion glycolysis and total metabolic tumour volume, which quantify not just how bright a lesion is but how much metabolically active tissue it contains, though the SUVmax comparisons dominated the significant findings.

Why should two tumours arising from the same primordial germ cell lineage differ so markedly in their sugar consumption? Seminomas are histologically homogeneous, composed of sheets of uniform cells resembling primitive spermatogonia, whereas non-seminomatous tumours can contain wildly divergent components, from gland-like yolk sac structures to syncytiotrophoblasts that secrete human chorionic gonadotropin. Embryonal carcinoma elements, in particular, are highly proliferative and express patterns of gene activity reminiscent of pluripotent stem cells, states that are metabolically expensive. Rapid proliferation demands nucleotide synthesis, lipid production and continuous ATP generation, all of which push cells toward intensified glycolysis and upregulated glucose transporters. The doubled SUVmax observed in non-seminomatous tumours is thus plausibly a readout of this underlying developmental chaos, though the study was not designed to identify the molecular mechanisms responsible.

The practical implications, if confirmed, could be meaningful. A pretreatment PET/CT that hints at histology could help clinicians anticipate the tumour type in settings where biopsy material is limited or ambiguous, flag patients at higher risk of harboring metastatic disease, and potentially refine surveillance strategies after orchiectomy. The authors themselves are appropriately measured, describing their work as a retrospective exploratory study of thirty patients from a single centre and calling for validation in larger, independent and ideally prospective cohorts. Such studies would need to address selection bias, scanner variability across institutions and the heterogeneity of non-seminomatous histologies. Still, the core observation stands out for its simplicity: before a single drop of chemotherapy, the two great families of testicular germ cell tumour already glow differently on a glucose scan, and that difference survives statistical scrutiny even when tumour size and spread are taken into account. It is a vivid reminder that cancer metabolism is not merely a byproduct of malignancy but a window into what a tumour truly is.

Subject of Research: Metabolic characteristics of testicular germ cell tumours on pretreatment ¹⁸F-FDG PET/CT imaging

Article Title: Pretreatment ¹⁸F-FDG PET/CT metabolic characteristics of seminoma and non-seminomatous testicular germ cell tumours: a retrospective exploratory study

Article References: Zhu, Y., Lu, X., Lin, L., Wang, H., Yu, Q., & Su, X. (2026). Pretreatment ¹⁸F-FDG PET/CT metabolic characteristics of seminoma and non-seminomatous testicular germ cell tumours: a retrospective exploratory study. BMC Medical Imaging. https://doi.org/10.1186/s12880-026-02855-6

Image Credits: AI Generated

DOI: 10.1186/s12880-026-02855-6

Keywords: testicular cancer, testicular germ cell tumour, seminoma, non-seminomatous germ cell tumour, ¹⁸F-FDG PET/CT, SUVmax, tumour metabolism, metabolic tumour volume, alpha-fetoprotein, cancer imaging, BMC Medical Imaging, diagnostic imaging

The study, led by Claudio Sallemi of the Interventional Radiology Unit at Fondazione Poliambulanza Istituto Ospedaliero, describes four consecutive patients with ruptured hepatocellular carcinoma treated with an unusual embolic material: a low-viscosity ethylene vinyl alcohol copolymer marketed as Squid Peri12. These agents, known as non-adhesive liquid embolic agents, consist of the EVOH copolymer dissolved in dimethyl sulfoxide, a solvent that diffuses rapidly into the bloodstream once the mixture is injected. As the solvent leaves, the copolymer precipitates in a slow, controlled fashion, solidifying into a soft, cohesive cast that conforms precisely to the twisted architecture of tumor vessels. The behavior is often described by operators as a lava effect, a gradual filling rather than the near-instantaneous gluing seen with older cyanoacrylate adhesives. Squid Peri12 is notable as the only EVOH-based agent with a kinematic viscosity of just 12 centistokes, a watery consistency that allows it to travel deep into fragile, tortuous tumor feeders that thicker agents might never reach.

All four patients arrived with the classic signature of rupture: acute anemia, hemodynamic decompensation, and free blood in the abdomen visible on non-contrast computed tomography. None was a candidate for emergency surgery, whether because of the sheer extent of the tumors, serious comorbidities, or outright instability. Conservative management with fluids and transfusions had failed to stabilize them. The tumors themselves were formidable, with a median diameter of 8.2 centimeters and a range stretching to 12.7 centimeters, all intensely hypervascular and all meeting the strictest LI-RADS 5 imaging criteria for hepatocellular carcinoma. One patient carried two bleeding lesions, one in each lobe. Two showed ominous local extension, one with suspected invasion of the adrenal gland and inferior vena cava plus segmental portal vein thrombosis, the other with a bulky mass displacing the gastric wall. In two patients alpha-fetoprotein, the blood marker that often tracks liver cancer activity, was elevated to as much as 3500 nanograms per milliliter.

The technical execution reveals how much finesse modern embolization demands. Procedures were performed under local anesthesia with mild sedation, using a slender 5 French sheath inserted through the radial or femoral artery. After mapping the hepatic arterial tree with a 4 French catheter, the operators advanced a DMSO-compatible microcatheter barely wider than a human hair into the subsegmental or even intralesional vessels feeding the tumor. Squid Peri12 was then injected at a deliberately slow rate of roughly 0.2 milliliters per minute under continuous fluoroscopy, allowing the team to watch the polymer cast grow in real time and stop the instant it threatened to escape into healthy territory. When reflux toward a larger artery appeared, the operators paused briefly to let the material partially polymerize, then resumed injection to push the cast deeper, a maneuver they call cast and push, adapted from the neurointerventional suites where EVOH agents have long been used for brain vascular malformations.

The results were striking on every measure the team recorded. Technical success was achieved in all four cases, with immediate hemostasis confirmed on post-procedural angiography and total embolic volumes of only 1 to 2.5 milliliters per patient. Fluoroscopy times averaged just 12 minutes despite the vascular complexity of the lesions. Crucially, no procedure-related adverse events occurred at all: no non-target embolization, no catheter entrapment, no post-embolization syndrome, no rebleeding, and no portal vein thrombosis. Liver function remained stable in three patients, while the fourth showed a transient rise in the liver enzyme AST from 63 to 358 units per liter, formally graded as a CTCAE version 5.0 grade 3 event but without any clinical deterioration or symptoms. Every patient was discharged home within three to five days, an outcome that would have been unthinkable a generation ago for patients bleeding to death from a burst liver tumor.

What followed over the next six months is what elevates this report from a hemostasis story to an oncology story. Follow-up CT scans at one, three, and six months, analyzed with modified RECIST criteria and semi-automatic volumetric software, showed sustained devascularization and consistent tumor shrinkage in every patient, with an average volume reduction approaching 60 percent and no additional transarterial or systemic therapy of any kind. Two patients, including the one whose tumor had appeared to invade the adrenal gland and vena cava, became eligible for curative-intent surgery after the embolization alone. In the operating room the suspected adrenal invasion was confirmed, an adrenalectomy was performed, and the resection was completed with preservation of the kidney. A third patient, initially inoperable because of gastric wall displacement and an alpha-fetoprotein level of 3500 nanograms per milliliter, experienced such marked regression that her marker fell to 27 nanograms per milliliter, rendering her a surgical candidate, though she ultimately declined the operation. The fourth patient achieved a complete radiologic response and remained disease-free without any further treatment.

The mechanistic explanation for this unexpected anti-tumor effect likely lies in the depth and permanence of the embolic cast. Particulate agents, the workhorses of conventional embolization, occlude vessels at a certain caliber but leave distal vascular networks patent, allowing tumors to reconstitute their blood supply over time. Cyanoacrylate glues polymerize on contact with blood, achieving rapid occlusion but demanding considerable operator skill and carrying a real risk of gluing the catheter in place or showering adjacent vessels with unintended emboli. The gradual precipitation of EVOH, by contrast, permits progressive, controlled filling of the entire intratumoral vascular bed, from feeding artery down to the smallest sinusoidal channels. A tumor stripped of its vasculature at that level cannot easily recover, and the ischemic injury may extend well beyond what a temporary particulate occlusion inflicts. The authors suggest this could explain both the sustained devascularization and the volume reductions observed without any adjunctive chemotherapy or immunotherapy.

The implications reach beyond the emergency setting. Hepatocellular carcinoma is typically diagnosed in patients with chronic liver disease, where every milliliter of functioning hepatic reserve matters and where treatment options for large or locally advanced tumors are painfully limited. If a single embolic session can downstage locally advanced disease to resectability, as it apparently did in two of these four patients, the low-viscosity EVOH approach could earn a place in planned, non-emergent treatment algorithms, potentially in combination with or as an alternative to conventional chemoembolization and radioembolization. The authors are careful to frame this as a hypothesis rather than a conclusion, noting that prior multicenter work has already established the safety of EVOH agents in acute non-neurovascular abdominal bleeding, but that their role in ruptured hepatocellular carcinoma had never been explored until now.

Honest caveats temper the enthusiasm. This was a retrospective case series of four patients, the weakest tier of clinical evidence, formally classified as Level 4. The absence of a comparison group means the tumor shrinkage cannot be definitively attributed to the embolic agent rather than to the general effect of devascularization, and rare complications may simply not have surfaced in so small a cohort. The team itself, which also included Maria Parmigiani, Marco Garatti, and Massimo Graffeo, calls explicitly for larger prospective studies to confirm the findings and define the role of EVOH agents beyond emergent indications. Still, the combination of flawless technical outcomes, preserved portal vein patency, stable liver function, and two unexpected conversions to curative surgery is difficult to dismiss as coincidence.

For a complication that has long carried a grim prognosis, the message of this small study is quietly revolutionary: the material used to plug a bleeding liver tumor in the middle of the night may also be a weapon against the tumor itself. If prospective trials bear out what these four patients experienced, the emergency catheter lab could become an unexpected starting point on the road to cure for some of the sickest liver cancer patients in the hospital.

Subject of Research: Emergency transarterial embolization of ruptured hepatocellular carcinoma using a low-viscosity EVOH copolymer and its potential tumor-shrinking effects

Article Title: Transarterial embolization with a low-viscosity ethylene vinyl alcohol (EVOH) copolymer for ruptured hepatocellular carcinoma: an oncologic role beyond hemostasis

Article References: Sallemi, C., Parmigiani, M., Garatti, M., & Graffeo, M. (2025). Transarterial embolization with a low-viscosity ethylene vinyl alcohol (EVOH) copolymer for ruptured hepatocellular carcinoma: an oncologic role beyond hemostasis. CVIR Oncology, 1(1), Article 24. https://doi.org/10.1007/s44343-025-00023-1

Image Credits: AI Generated

DOI: 10.1007/s44343-025-00023-1

Keywords: hepatocellular carcinoma, ruptured HCC, transarterial embolization, EVOH copolymer, Squid Peri12, liquid embolic agent, interventional radiology, tumor downstaging, liver cancer, hemostasis, alpha-fetoprotein, DMSO-compatible microcatheter

The tool designed to close that gap is surveillance, the repeated testing of asymptomatic people at risk of a disease so that it can be detected early. All major international professional bodies, including the European Association for the Study of the Liver, the American Association for the Study of Liver Disease and the Asian Pacific Association for the Study of the Liver, recommend that patients with cirrhosis and high-risk chronic hepatitis B undergo liver ultrasound with or without serum alpha-fetoprotein measurement every six months. The annual risk of developing hepatocellular carcinoma in chronic liver disease ranges from about 1 per cent in alcohol-related cirrhosis to 2 per cent in hepatitis B and 3 to 8 per cent in hepatitis C. But a comprehensive review published in The Lancet Regional Health – Europe reveals that the evidence underpinning this universal recommendation is far shakier than most clinicians and patients realise, and that the gap between what guidelines advise and what actually happens in clinics is enormous.

The mortality benefit of surveillance rests largely on a single randomised controlled trial conducted in China, which found that six-monthly ultrasound with or without alpha-fetoprotein reduced hepatitis B-related liver cancer mortality by 37 per cent. No subsequent randomised study has ever replicated the finding, and further trials are widely considered unfeasible or unethical. In one Australian feasibility study, 99.5 per cent of patients declined randomisation to a no-surveillance arm. In place of trial data, the field relies on cohort studies and modelling: a meta-analysis of 59 international studies involving 145,396 patients found that surveillance was associated with earlier-stage diagnosis, higher receipt of curative treatment and improved overall survival after adjustment for lead-time bias. Critics counter that a trial in largely non-cirrhotic hepatitis B carriers may not generalise to older, sicker cirrhotic populations facing competing causes of death, a concern underscored by Danish registry data showing that liver cancer contributes only modestly to mortality in alcohol-related cirrhosis.

The surveillance test itself is also under scrutiny. Ultrasound is operator-dependent, with a sensitivity of just 47 per cent for early disease, and performance deteriorates further in patients with obesity or advanced cirrhosis. Around 20 per cent of surveillance ultrasounds are judged inadequate to visualise the liver, a particularly troubling statistic as metabolic dysfunction-associated steatotic liver disease, or MASLD, surges across populations with rising adiposity. Computed tomography and magnetic resonance imaging can be substituted when visibility is poor, but no randomised evidence supports cross-sectional imaging for surveillance, and cost, radiation and cumulative gadolinium exposure limit enthusiasm. Meanwhile, the harms of surveillance, physical, financial and psychological, have never been systematically quantified at scale. One United States study found physical harms in 27 per cent of patients, and emerging work highlights anxiety, false positives and out-of-pocket costs as meaningful burdens whose weight likely varies with a patient’s baseline cancer risk.

Against this contested backdrop, actual uptake of surveillance is dismal. A recent meta-analysis of 49 studies covering more than 1.2 million patients found that while 54 per cent of eligible people received some surveillance, fewer than 10 per cent received the guideline-concordant biannual testing. Country-level figures expose the patchwork: biannual uptake is around 17 per cent in the United Kingdom, 8 per cent in France, 4 per cent in Norway and under 20 per cent in the United States, compared with roughly 80 per cent in Japan and 75 per cent in Taiwan. Barriers span three levels. Patients may lack awareness of their risk or face logistical and financial constraints; clinicians report limited knowledge, time pressure and scepticism about the guidelines; and health systems lack national programmes, registries and recall infrastructure to keep at-risk patients in the loop.

Europe’s institutional response has been strikingly ambivalent. Europe’s Beating Cancer Plan, launched in 2021 with 4 billion euros earmarked for cancer action, explicitly declines to support liver cancer surveillance, with the European Commission stating that screening elevated-risk people entails uncommon but serious harms and might not reduce mortality. The United States National Cancer Institute draws a similarly pessimistic conclusion from the same Chinese trial. Professional societies, meanwhile, continue to recommend surveillance, leaving patients and advocacy groups lobbying for care that many clinicians, awaiting formal national guidance, remain reluctant to organise. The authors of the review argue that this deadlock leaves cirrhotic and viral hepatitis patients in a state of flux, receiving variable care in a disease that disproportionately affects society’s most marginalised members.

The contrast with countries that have committed to national programmes is instructive. Japan, the first nation to implement organised liver cancer surveillance, built its system in the 1980s through close cooperation between the Japan Society of Hepatology, government ministries and frontline hospitals. Super-high-risk patients, such as those with viral cirrhosis, are scanned every three to four months with ultrasound plus three tumour markers, alpha-fetoprotein, AFP-L3 and PIVKA-II, with optional dynamic CT or Gd-EOB-MRI once or twice a year. Ultrasounds are frequently performed directly by hepatologists rather than radiologists, and an annual eradication campaign, nationwide hepatitis testing and electronic record alerts keep risk populations engaged. The results are unmatched: more than 80 per cent of high-risk individuals covered, 65 per cent of cancers diagnosed at early BCLC stage 0 or A, and a five-year survival of 43 per cent, more than double the European figure. Taiwan pairs a reimbursed surveillance programme with its hepatitis B vaccination success, while Egypt offers free lifelong four-monthly monitoring through 58 specialised units. Thailand has shown that risk scores and the GAAD biomarker panel can cut the surveillance-eligible population dramatically and cost-effectively.

Within Europe itself, national philosophies diverge sharply. Denmark restricts surveillance to viral hepatitis and PAGE-B high-risk patients, judging the evidence insufficient for alcohol-related or MASLD-related cirrhosis, where local registry data show an annual cancer incidence of just 0.7 per cent; it is now trialling surveillance for all cirrhosis patients in one region to generate better evidence. Spain operates a clinician-led, risk-stratified model with uptake approaching 80 per cent in specialised care, though only 47 per cent of national cases are detected through surveillance. The United Kingdom, despite running the world’s largest universal healthcare system, records some of the worst hepatobiliary cancer outcomes among wealthy nations, with under 20 per cent of patients receiving curative therapy and emergency presentation the most common route to diagnosis. A community pilot programme has referred 7,892 patients to hepatology, but no formal health-economic evaluation has yet been published, and the country still lacks a national cirrhosis registry.

The patient experience, often overlooked in policy debates, adds a further layer of urgency. A British Liver Trust survey of 135 people affected by primary liver cancer found surveillance frequently undermined by poor communication, inconsistent delivery and stigma. Patients reported not understanding what the scans were for, being forgotten by their liver teams, waiting more than six months for appointments and travelling over 20 miles for care. Many described feeling blamed for their disease, with assumptions about alcohol use shaping their engagement with services. The review’s authors argue that surveillance must be reframed as a patient-centred pathway, consistent, clearly communicated, stigma-aware and locally accessible, or it risks reinforcing the very inequalities it is meant to counter.

The path forward, the authors suggest, lies in three converging innovations. First, risk stratification: tools such as the aMAP score, FIB-4 index, the Toronto HCC risk index and elastography-based stiffness measures could concentrate resources on those most likely to benefit, an approach already trimming eligible populations in Thailand and Denmark. Second, novel biomarkers: the GALAD score has passed phase III validation, outperforming alpha-fetoprotein in detecting cancer up to 12 months before diagnosis, while methylated DNA panels such as mt-HBT and HelioLiver show comparable early-stage sensitivity, and patients consistently prefer blood tests to ultrasound. Third, abbreviated MRI, a faster, cheaper imaging protocol now being tested in multiple international trials, may serve populations poorly served by ultrasound, particularly those with MASLD. The authors’ key recommendations call for a large multinational risk-based trial, research into alternative modalities, free surveillance at the point of care, patient navigation programmes and coordinated advocacy by professional societies and patient groups toward the European Commission and National Cancer Institute. With MASLD projected to become the leading cause of liver cancer, often arising even without cirrhosis, the authors warn that Europe’s current deadlock is untenable: further observational studies will not convince sceptics, and only pragmatic, risk-based, well-funded programmes, on the model of Japan, Taiwan and Egypt, can translate four decades of partial evidence into falling mortality.

Subject of Research: Hepatocellular carcinoma surveillance practices, evidence and barriers in Europe and globally

Article Title: Hepatocellular carcinoma surveillance in Europe: challenges and lessons from global practice

Article References: Qurashi, M., Buti, M., Lai-Hung Wong, G., Qureshi, H., Kudo, M., Tanwandee, T., Chen, C.-J., Abdelaziz, A. O., AbdAllah, M., Howell, J., Hebditch, V., Singal, A. G., Jepsen, P., & Sharma, R. (2026). Hepatocellular carcinoma surveillance in Europe: challenges and lessons from global practice. The Lancet Regional Health – Europe, 70, Article 101852. https://doi.org/10.1016/j.lanepe.2026.101852

Image Credits: AI Generated

DOI: 10.1016/j.lanepe.2026.101852

Keywords: hepatocellular carcinoma, liver cancer, surveillance, cirrhosis, ultrasound, alpha-fetoprotein, MASLD, hepatitis B, GALAD biomarker, abbreviated MRI, risk stratification, Europe

Congenital portosystemic shunts are rare malformations in which blood flowing through the portal vein, which normally delivers nutrient-rich blood from the intestines to the liver for processing, bypasses the liver entirely and drains directly into the systemic venous system. In this patient, the malformation was classified as a Park type I shunt, the category in which an abnormal vessel connects the portal circulation directly to the inferior vena cava. The consequences of such a shortcut are profound. Deprived of its full portal blood supply, the liver may fail to grow and develop normally, and a cascade of metabolic and hormonal disturbances can follow, because substances that would ordinarily be cleared or processed by the liver pass unfiltered into the general circulation. Among the most serious long-term consequences documented in the literature is an elevated risk of hepatic tumors, including hepatocellular carcinoma and, far more rarely, hepatoblastoma, the most common malignant liver tumor of early childhood.

Hepatoblastoma on its own is already a formidable diagnosis, typically arising in children under three years of age and demanding a combination of chemotherapy and surgical resection for any chance of cure. When the disease appears multifocally, meaning it involves several distinct regions of the liver rather than a single mass, surgical planning becomes considerably more complex. In this case the tumor was staged as PRETEXT stage III, a designation indicating that three of the four sections of the liver were involved, leaving only one contiguous healthy section. In a liver already compromised by a portosystemic shunt, with abnormal perfusion and potentially reduced functional reserve, the surgical team faced a clinical puzzle with no established playbook. The authors of the report emphasize that standardized diagnostic and therapeutic protocols for managing congenital portosystemic shunts accompanied by multifocal hepatoblastoma simply do not exist, forcing clinicians to improvise on the basis of first principles and close multidisciplinary collaboration.

The strategy the team ultimately pursued was deliberately sequenced. First, they performed an anatomical segment IV resection, removing the dominant tumor along with the entire liver segment in which it was based, an approach designed to secure clear margins rather than simply shelling out the visible mass. Critically, they combined this resection with concurrent closure of the congenital shunt in the same operative session. The shunt was occluded using a patent ductus arteriosus occluder, a device originally engineered to close abnormal openings between the great vessels of the heart, repurposed here to plug the aberrant portosystemic channel. Restoring normal portal blood flow to the liver is not merely a corrective maneuver for the vascular defect; it also matters for oncologic control, because re-establishing proper hepatic perfusion supports liver regeneration and function after major resection, and it removes the abnormal hemodynamic environment that is thought to contribute to tumor formation in these patients.

Once the dominant mass had been removed and the shunt closed, the team turned to the remaining multifocal tumor deposits. Instead of additional resections, which would have consumed precious liver volume in a child whose organ was already under strain, they deployed ultrasound-guided microwave ablation. Microwave ablation uses high-frequency electromagnetic waves to induce rapid heating within tumor tissue, causing coagulative necrosis at precisely targeted locations. Guided by real-time ultrasound, the surgeons could treat each residual lesion while sparing the surrounding healthy parenchyma, an advantage of particular importance in multifocal disease where the goal is to preserve as much functional liver as possible. The combination of anatomical resection for the largest lesion and ablation for the smaller deposits represents an elegant tissue-sparing division of labor that the authors argue may serve as a reference model for similar cases in the future.

Chemotherapy completed the treatment protocol, acting as a systemic safeguard against microscopic disease that imaging cannot detect. The specific regimen details illustrate the standard armamentarium of pediatric hepatoblastoma therapy, adapted to the patient’s recovery from major surgery. What distinguishes this case is not any single component, since each element, whether resection, ablation, chemotherapy, or shunt closure, is individually established in clinical practice, but the integration of all four into a coherent, coordinated plan executed across surgical oncology, interventional radiology, and pediatric oncology disciplines. The authors describe the protocol as safe and feasible based on their experience, and the outcome lends weight to that assessment: the shunt was successfully occluded, complete local tumor control was achieved, and the child has remained well through a ten-month follow-up period.

Surveillance in this case rested on three complementary pillars. Serial monitoring of alpha-fetoprotein, a protein produced abundantly by hepatoblastoma cells and normally present at high levels in newborns but declining through infancy, provided a sensitive biochemical indicator of any residual or recurrent tumor activity. Contrast-enhanced abdominal magnetic resonance imaging offered detailed anatomical assessment of the liver, allowing clinicians to verify that the ablated zones contained no viable tumor and that the liver itself was regenerating as expected after resection. Chest computed tomography completed the picture by excluding pulmonary metastases, the most common site of distant spread in hepatoblastoma. The convergence of a normalized alpha-fetoprotein trend, clean imaging, and the child’s clinical well-being at ten months constituted strong evidence of complete remission, though the authors are careful to frame the follow-up interval as meaningful rather than definitive, given the long horizon over which pediatric liver tumors can recur.

The broader significance of the case extends beyond a single patient. Congenital portosystemic shunts were once considered almost incidental findings, but accumulated evidence over recent decades has established that they carry real long-term risks, including hepatic encephalopathy, portopulmonary hypertension, liver nodules, and malignancy. The association between shunts and hepatoblastoma, while exceedingly rare, underscores the importance of longitudinal surveillance in children diagnosed with these vascular anomalies. This case also demonstrates that the traditional staging logic for hepatoblastoma, which assumes a normally perfused liver, must be adapted when a shunt alters hepatic hemodynamics. The Shenzhen team’s decision to address the shunt and the tumor simultaneously reflects a growing recognition that in complex congenital disease, fragmenting care among specialties that do not coordinate can compromise outcomes that an integrated plan could achieve.

Technically, the case highlights the versatility of devices and techniques crossing traditional disciplinary boundaries. The use of a patent ductus arteriosus occluder for shunt closure borrows from interventional cardiology, while microwave ablation is a technology shared between hepatology, radiology, and surgical oncology. Anatomical liver resection in a toddler demands precision given the small size of the liver and the limited tolerance for volume loss, and combining it with endovascular occlusion in the same anesthetic session required careful intraoperative planning. The report, supported by the Sanming Project of Medicine in Shenzhen and approved by the ethics committee of Shenzhen Children’s Hospital with written informed consent from the child’s legal guardians, is presented as an early-release, peer-reviewed, citable account intended to give clinicians confronting similar cases a documented precedent where none previously existed.

For the scientific and medical community, the message is twofold. First, children with congenital portosystemic shunts deserve vigilant, structured follow-up that includes liver imaging and tumor marker surveillance, because the risk of hepatic malignancy, though rare, is real and potentially curable when caught early. Second, when malignancy does arise in this setting, the experience from Shenzhen suggests that a single-stage approach combining anatomical resection of the dominant lesion, concurrent shunt closure, ultrasound-guided microwave ablation of satellite tumors, and adjuvant chemotherapy can deliver excellent local control without overwhelming the liver’s limited reserve. Ten months after surgery, a two-year-old who faced a combination of anomalies that most pediatric surgeons will never encounter is free of disease, and the medical literature has gained a template for the next patient unlucky enough to share the diagnosis.

Subject of Research: A rare pediatric case of congenital portosystemic shunt complicated by multifocal hepatoblastoma treated with multidisciplinary therapy.

Article Title: Multidisciplinary management of congenital portosystemic shunt complicated by multifocal hepatoblastoma: a case report

Article References: Multidisciplinary management of congenital portosystemic shunt complicated by multifocal hepatoblastoma: a case report. (n.d.). https://doi.org/10.1186/s12887-026-07743-0

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07743-0

Keywords: congenital portosystemic shunt, hepatoblastoma, pediatric liver tumor, microwave ablation, alpha-fetoprotein, multidisciplinary management, liver resection, Park type I shunt, PRETEXT staging, chemotherapy, BMC Pediatrics, case report